Source: Stat News

“Unfortunately, I am unable to support one of the 16 titles in front of the Energy and Commerce Committee,” Peters said, referring to the provision that includes Pelosi’s drug pricing plan.

The panel has not yet voted, and the drug pricing vote is expected as soon as Tuesday. If all three members follow through, the measure would fail.

A spokesperson for Energy & Commerce Chair Frank Pallone (D-N.J.) said that the markup is ongoing, and that Pallone is working to ensure all provisions are passed out of committee.

Peters, Rice, and Schrader all voted to pass a nearly identical version of Pelosi’s drug pricing bill in December 2019, and all voted again in June 2020 to pass a health care package including the policy. Those were messaging bills that didn’t have a path to passage in the Republican-led Senate last Congress, however.



Read more: https://www.statnews.com/2021/09/14/house-moderates-rebel-against-pelosi-drug-pricing-plan-leaving-bills-fate-uncertain/?utm_campaign=rss